Get the Stockscreener App
1.65
9.27%
0.14
After Hours:
1.65
NanoViricides Inc stock is traded at $1.65, with a volume of 813.00K.
It is up +9.27% in the last 24 hours and up +35.25% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.51
Open:
$1.52
24h Volume:
813.00K
Relative Volume:
0.93
Market Cap:
$37.92M
Revenue:
-
Net Income/Loss:
$-8.09M
P/E Ratio:
-3.7896
EPS:
-0.4354
Net Cash Flow:
$-7.37M
1W Performance:
+10.00%
1M Performance:
+35.25%
6M Performance:
+37.50%
1Y Performance:
+18.28%
1-Day Range:
$1.52
$1.6777
1-Week Range:
$1.45
$1.6782
52-Week Range:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.65 | 34.70M | 0 | -8.09M | -7.37M | -0.4354 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Alliance Global Partners | Buy |
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
Oral Ebola drug gummies clear key ethics hurdle as Congo outbreak widens - Stock Titan
NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola - Stocktwits
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Argus Leader
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
NanoViricides Receives Outperform Rating and $6 Price Target from Noble Capital Markets - citybuzz -
NanoViricides Inc. (NNVC) Q2 2026 Earnings: EPS Beat but No Revenue; Stock Declines 1.01%Earnings Revision Upgrade - dars.gov.et
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily - ACCESS Newswire
symbol__ Stock Quote Price and Forecast - CNN
NanoViricides Price Target Announced at $6.00/Share by Noble Capital Markets - Moomoo
Noble Capital initiates NanoViricides stock with Outperform rating By Investing.com - Investing.com South Africa
Noble Financial Initiates Nanoviricides(NNVC.US) With Buy Rating, Announces Target Price $6 - Moomoo
NanoViricides Advances NV-387 Oral Gummies Toward Phase II Trial for Bundibugyo Ebola in DRC - citybuzz -
Noble Capital initiates NanoViricides stock with Outperform rating - Investing.com
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo - ACCESS Newswire
NanoViricides moves NV-387 oral gummies toward DRC Ebola trial - Stock Titan
Enterprise value to revenue forward of NanoViricides, Inc. – AMEX:NNVC - TradingView
NNVCNanoViricides Inc Website Traffic and Mobile Apps Usage - Finviz
Price to book forward of NanoViricides, Inc. – AMEX:NNVC - TradingView
Enterprise value to revenue forward of NanoViricides, Inc. – SWB:NV3P - TradingView
NNVC Q2 2026 Earnings: Narrower-than-Expected Loss as R&D Pipeline AdvancesOne-Time Gain Impact - DonanımHaber
Price to earnings forward of NanoViricides, Inc. – AMEX:NNVC - TradingView
NNVC Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock MovementOperating Income Trends - dars.gov.et
FDA rare pediatric disease designation could speed a measles drug review - Stock Titan
[EFFECT] NANOVIRICIDES, INC. SEC Filing - Stock Titan
NanoViricides (NNVC) Gains 3% as Stock Approaches Key ResistanceSupply Zone - DonanımHaber
NanoViricides, Inc. Actuals & Estimates (MUN:NV3P) - TradingView
NanoViricides, Inc. Actuals & Estimates (AMEX:NNVC) - TradingView
NanoViricides, Inc. Actuals & Estimates (LS:A2PSNF) - TradingView
NNVC Forecast — Price Target — Prediction for 2027 - TradingView
A2PSNF Forecast — Price Target — Prediction for 2027 - TradingView
REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan - Yahoo Finance
NanoViricides Inc (NNVC) Institutional Confidence - TradingKey
NanoViricides Ships NV-387 to DRC for Phase II MPox Trial - MEXC
NanoViricides sends oral NV-387 to Congo for Phase II trial prep - Stock Titan
NNVC Q1 2026 Earnings: Narrower-than-expected loss and positive stock reactionEarnings Growth Forecast - dars.gov.et
NanoViricides Inc (NNVC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NanoViricides Inc (NNVC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NanoViricides Inc (NNVC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NanoViricides Inc (NNVC) Valuation: PE, PB & Fair Value Analysis - TradingKey
NanoViricides Inc (NNVC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NanoViricides Inc (NNVC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nanoviricides | DEL AM: Others - Moomoo
NanoViricides Receives DRC Approval to Advance Phase II Ebola Trial for Oral Antiviral NV-387 - citybuzz -
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of EbolaNanoViricides Proposal is Approved by the Pillar Committee in DR Congo - ACCESS Newswire
NNVC Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentEarnings Expansion Phase - newsline.com
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatmentwith Superior Oral Administration and Escape Resistance Features Over Antibodies - ACCESS Newswire
NanoViricides pushes chewable Ebola drug trial as Congo outbreak escalates - Stock Titan
NanoViricides Files for $50 Million Mixed Shelf Offering - Moomoo
NNVC stock up 17% today: What’s driving the rally? - MSN
NanoViricides (NNVC) Edges Lower Within Narrow Trading RangePre-Earnings Momentum - newsline.com
NanoViricides (NNVC) Slides 3.6% as Selling Pressure IntensifiesInstitutional Buy Signals - The Legal Advocate
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.60%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):